Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Servier Canada.

    Client Virtual Booth

    SERVIER CANADA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Servier Canada
    Canada Flag
    Country
    Country
    Canada
    Address
    Address
    235, boul. Armand-Frappier Laval (Quebec) H7V 4A7
    Telephone
    Telephone
    450-978-9700
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.servier.ca/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/servier-canada
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Servier Agrees to Buy Symphogen to Swell its Cancer Pipeline

    Details:

    Servier will gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and Symphogen’s antibody discovery and development platform.


    Lead Product(s): Sym021

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Phase IProduct Type: Large molecule

    Recipient: Symphogen

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition April 03, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products

    Details:

    Cellectis grants to Servier an expanded exclusive worldwide license to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19.


    Lead Product(s): UCART19

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Phase IProduct Type: Cell and Gene therapy

    Recipient: Cellectis

    Deal Size: $410.0 million Upfront Cash: $27.6 million

    Deal Type: Collaboration March 04, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search